TEVA Q4 2023 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena

TEVATeva Pharmaceutical Industries Limited

$37B

Q4 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$4.5B+14.8% YoY

Gross Profit

$2.4B54.2% margin

Operating Income

$756M17.0% margin

Net Income

$463M10.4% margin

EPS (Diluted)

$0.41

QoQ Revenue Growth

+15.8%

Cash Flow

Operating Cash Flow

$1.2B

Free Cash Flow

$1.1B

Stock-Based Comp.

$28M

Balance Sheet

Total Assets

$43.5B

Total Liabilities

$35.4B

Stockholders' Equity

$7.5B

Cash & Equivalents

$3.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.5B	$3.9B	+14.8%
Gross Profit	$2.4B	$1.8B	+36.5%
Operating Income	$756M	-$855M	+188.4%
Net Income	$463M	-$1.2B	+137.9%

Revenue Segments

Product

$3.3B73%

License

$547M12%

Distribution Service

$402M9%

Product and Service, Other

$252M6%

Geographic Segments

North America Segment

$2.4B56%

Europe Segment

$1.3B32%

International Markets

$502M12%